Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer in court over Chinese stealing trade secrets

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 08, 2023 2:02pm

121 Views

Post# 35275024

RE:RE:RE:RE:Pfizer in court over Chinese stealing trade secrets

"Do you think Oncy’s association with Chinese co. Adlai Nortye could be detrimental to a buyout by not only Pfizer, but by any big pharma? "

I would think that Big Pharma have generally equally made that determination based on the recently passed IRA provisions by the US Congress and signed into law by USPOTUS in August 2022.

Soon after August 2022, this board learned that Adlai Nortye no longer had pelareorep listed in its clinical trial list nothwithstanding that in December 2022 Adlai Nortye reported postive results in the pelareorep + paclitaxel Phase 2 "Bridging" Clinical Trial.

I would also think that Adlai Nortye had willing "surrendered" their licensing agreement with ONCY knowing that ONCY would be acquired by Big Pharma, and that this agreement would be void/nil with ONCY becoming the "merging company" into the Big Pharma "surviving company". So in order to favorably hedge Adlai Nortye's position with the Big Pharma "surviving company" for potentil future considerations, Adlai Nortye complied with "surrendering" the license to make the M&A acquisition of ONCY go smoothly to completion.

https://www.oncolyticsbiotech.com/press-releases/detail/589/oncolytics-biotechs-chinese-development-partner-adlai

<< Previous

Bullboard Posts

Next >>

UniDoc brings AI-powered H3 Health Cube to Italy